Pashtoon Kasi: Why would neoadjuvant immunotherapy work better
Pashtoon Kasi shared a post on LinkedIn:
“AWhy would immunotherapy work better when given before surgery (neoadjuvant) when the tumor is still in the body?
Resection not only takes bulk of the tumor but also the tumor-infiltrating lymphocytes.
Increase T cells to antigens exposure.”
Read further.
Source: Pashtoon Kasi/LinkedIn
Pashtoon Kasi is a medical oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Within his roles at Weill Cornell Medicine, he holds the positions of Director for Colorectal Cancer Research and Precision Medicine Director for Liquid Biopsy Research at the Englander Institute of Precision Medicine.
Previously, Dr. Kasi served as an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of Iowa, following positions as an Assistant Professor of Medicine and Oncology at both the University of Iowa and Mayo Clinic.
His research primarily focuses on “liquid biopsies,” particularly circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Dr. Kasi is also recognized as an author and editor of several significant books, including “Research: What, Why, and How: A Treatise from Researchers to Researchers” and “Impact of Circulating Tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies.” His scholarly contributions extend to over 100 publications in esteemed peer-reviewed journals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023